NIAID, National Institutes of Health - Wednesday, Dec. 8, 1999
John Bowersox, Laurie K. Doepel - (301) 402-1663
A single HIV protein acts as a molecular traffic signal to regulate crucial steps in the virus life cycle, a new study has found. The discovery of these previously unrecognized stop-and-go functions provides new targets for creating molecular gridlock and halting virus growth. A research team led by Michael R. Green, M
National Institute of Child Health & Human Development; National Institute of Allergy & Infectious Diseases - EMBARGOED FOR RELEASE - Wednesday, Aug. 4, 1999 5:00 p.m. Eastern Time
Robert Bock (NICHD) (301) 496-5133 John Bowersox (NIAID) (301) 402-1663
Two studies supported by the National Institutes of Health (NIH) provide compelling evidence that the amount of HIV in a pregnant woman s blood, known as the maternal HIV viral load, is the prime risk factor for transmitting the virus to her baby. Women who had high levels of HIV in their blood -- whether they received
National Institutes of Health, National Institute of Allergy and Infectious Diseases - FOR RELEASE Wednesday, July 14, 1999 12:00 p.m. Eastern Time
Office of Communications And Public Liaison (301) 402-1663
A joint Uganda-U.S. study has found a highly effective and safe drug regimen for preventing transmission of HIV from an infected mother to her newborn that is more affordable and practical than any other examined to date. Interim results from the study, sponsored by the National Institute of Allergy and Infectious Dise
National Institute of Allergy and Infectious Diseases. National Institutes of Health-- FOR RELEASE Tuesday, July 13, 1999 11:00 a.m. Eastern Time
Laurie K. Doepel (301) 402-1663 ldoepel@nih.gov
Preliminary analysis of data from a clinical trial testing two candidate HIV vaccines given together shows that the combination is safe and can stimulate diverse immune responses against HIV. The findings will be discussed by the study s principal investigator, Robert Belshe, M.D., of Saint Louis University, on Tuesday
National Institute of Allergy and Infectious Diseases, National Institutes of Health - EMBARGOED FOR RELEASE: Wednesday, May 26, 1999 5:00 p.m. Eastern Time
Laurie K. Doepel (301) 402-1663 ldoepel@nih.gov
Currently approved anti-HIV drug combinations are remarkably effective at reducing the amount of HIV in many patients to undetectable blood levels. For most, the clinical benefits add up to a healthier, longer life. Yet two studies in this week s New England Journal of Medicine demonstrate that, as good as these drugs
National Institute of Allergy and Infectious Diseases - Wednesday, May 5, 1999
Greg Folkers - (301) 496-2263 gfolkers@nih.gov
An updated version of the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents has been posted to the AIDS Treatment Information Service (ATIS) Web site, www.hivatis.org. The Guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection, a joint effort
National Institute of Allergy and Infectious Diseases - Tuesday, April 20, 1999
John Bowersox (301) 402-1663 jbowersox@nih.gov
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded five-year grants to continue the work of the Multicenter AIDS Cohort Study (MACS), the largest continually followed group of HIV-infected or at-risk individuals in the world. Approximately $6 million in first-year funding will be distributed
National Institutes of Allergy and Infectious Diseases - Thursday, April 8, 1999
Laurie K. Doepel (301) 402-1663 ldoepel@nih.gov
A new study from the Institute of Medicine (IOM) presents important information to help the research community set domestic vaccine priorities for the future. Vaccines for the 21st Century: A Tool for Decisionmaking, commissioned by the National Institute of Allergy and Infectious Diseases (NIAID), employs a new quanti
National Institutes of Allergy and Infectious Diseases - Thursday, March 11, 1999
Anne Thomas (301) 496-5787; Laurie K. Doepel (301) 402-1663
HHS Secretary Donna E. Shalala today announced that Gary Nabel, M.D., Ph.D., has been chosen as Director of the Vaccine Research Center (VRC) at the National Institutes of Health. The Center s initial focus is to develop candidate vaccines against HIV. President Clinton has challenged the nation to develop a vaccine ag
National Institute of Allergy and Infectious Diseases - Monday, Feb. 8, 1999
Laurie K. Doepel (301) 402-1663 ldoepel@nih.gov
The first AIDS vaccine trial in Africa, under preparation for years, has begun in Uganda . The opening of this Phase 1 trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is an important step in an attempt to develop HIV vaccines for countries hardest hit by the AIDS pandemic, commen
National Institute of Allergy and Infectious Diseases - Monday, Feb. 1, 1999
Sam Perdue sperdue@nih.gov; John Bowersox jbowersox@nih.gov (301) 402-1663
New Studies Offer Clues to AIDS Vaccine Design and Safety New studies by National Institute of Allergy and Infectious Diseases (NIAID) scientists and grantees help fill in pieces of the AIDS vaccine research puzzle. In three separate reports published in the February 1999 issue of the journal Nature Medicine, researche
National Institutes of Health, National Institute of Allergy and Infectious Dieases - Sunday, Jan. 31, 1999
Laurie K. Doepel, (301) 402-1663, ldoepel@nih.gov
Today scientists reported that they have discovered the origin of HIV-1, the virus responsible for the global AIDS pandemic. A subspecies of chimpanzees native to west equatorial Africa has been identified as the original source of the virus. Beatrice H. Hahn, M.D., of the University of Alabama at Birmingham, a grantee
National Institutes of Allergy and Infectious Diseases - Sunday, Jan. 31, 1999
Laurie K. Doepel (301) 402-1663 ldoepel@nih.gov
Today scientists reported that they have discovered the origin of HIV-1, the virus responsible for the global AIDS pandemic. A subspecies of chimpanzees native to west equatorial Africa has been identified as the original source of the virus. Beatrice H. Hahn, M.D., of the University of Alabama at Birmingham, a grantee
National Institute of Allergy and Infectious Diseases - Wednesday, Jan. 13, 1999
James Hadley (301) 402-1663 jh49c@nih.gov
Researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID) have developed a behavioral intervention that significantly reduced new cases of chlamydial infection and gonorrhea during a 12-month period among a group of African-American and Mexican-American women in health clinics in San An
National Institutes of Allergy and Infectious Disease - Tuesday, Jan. 12, 1999
Laurie K. Doepel (301) 402-1663 ldoepel@nih.gov
Children exposed to zidovudine (ZDV, AZT ) in utero and as newborns and who escaped acquiring HIV from their infected mothers show no cancers or other adverse health effects up through preschool age, according to a new study from the National Institutes of Health (NIH). It is the first report to assess the late effects
National Institutes of Health, National Institute of Allergy and Infectious Dieases: EMBARGOED FOR RELEASE: 12 JANUARY 1999 AT 16:00:00 ET US
Laurie K. Doepel, 301-402-1663 ldoepel@nih.gov
Children exposed to zidovudine (ZDV, AZT ) in utero and as newborns and who escaped acquiring HIV from their infected mothers show no cancers or other adverse health effects up through preschool age, according to a new study from the National Institutes of Health (NIH). It is the first report to assess the late effects
This information is designed to support, not replace, the relationship that exists between you and your doctor.